Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) posted 946 million yuan in profit attributable to shareholders of the listed company for the third quarter, up 15% from a year prior.

EPS moved 16.13% higher year over year to 0.36 yuan, a Tuesday filing with the Hong Kong Exchange showed.

For the three months ended Sept. 30, operating revenue was 10 billion yuan, an increase of 1.4% from the year-ago period, the company said.